张斌,裴志强,马登峰,邱金,任倩,赵淑珍

• 1:山西医科大学第九临床医学院太原市中心医院心内科
• 2:复旦大学附属中山医院心内科
• 3:长治医学院

摘要(Abstract)：

二尖瓣环钙化（MAC）是与年龄相关的局部纤维支持结构的慢性、退行性病变。目前研究认为它是类似动脉粥样硬化和主动脉瓣钙化主动发生的过程，都伴有脂蛋白（α）[Lp(α)]的沉积和慢性炎症灶的形成。其中，Lp(α)是研究的热点。近年来，Lp(α)与主动脉瓣钙化的关系得到了广泛关注，已有大量研究证明，升高的Lp(α)及其相关的氧化磷脂（OxPL）可以通过多种钙调节途径促进主动脉瓣钙化、狭窄，但MAC的病理生理过程是更加复杂和不明确的。目前Lp(α)与MAC的关系有了初步探索。本文将从MAC、Lp(α)以及两者之间的研究进展三方面进行综述，使两者目前的关系更加清晰，从而为预防或延缓MAC提供新的可能。

关键词(KeyWords)： 二尖瓣环钙化;脂蛋白(α);主动脉瓣钙化

Abstract:

Keywords:

基金项目(Foundation): 中国医学科学院中央级公益性科研院所基本科研业务费专项资金资助项目（2022-JKCS-30）

作者(Author): 张斌,裴志强,马登峰,邱金,任倩,赵淑珍

参考文献(References)：

• [1]周华兰,徐培敬,胡得飞,等.脂联素、同型半胱氨酸在退行性心瓣膜病患者中的水平变化及其临床意义[J].实用医学杂志,2012,28(3):383-385.DOI:10.3969/j.issn.1006-5725.2012.03.016.
• [2]Santangelo G,Bursi F,Faggiano A,et al.The global burden of valvular heart disease:from clinical epidemiology to management[J].J Clin Med,2023,12(6):2178.DOI:10.3390/jcm12062178.
• [3]Korn D,Desanctis RW,Sell S.Massive calcification of the mitral annulus.A clinicopathological study of fourteen cases[J].N Engl J Med,1962,267:900-909.DOI:10.1056/NEJM196211012671802.
• [4]Nestico PF,Depace NL,Morganroth J,et al.Mitral annular calcification:clinical,patho p hysiolo gy,and echocardiographic review[J].Am Heart J,1984,107(5 pt1):989-996.DOI:10.1016/0002-8703(84)90840-8.
• [5]De Backer O,Piazza N,Banai S,et al.Percutaneous transcatheter mitral valve replacement:an overview of devices in preclinical and early clinical evaluation[J].Circ Cardiovasc Interv,2014,7(3):400-409.DOI:10.1161/CIRCINTERVENTIONS.114.001607.
• [6]Birudaraju D,Cherukuri L,Pranesh S,et al.Current methods to assess mitral annular calcification and its risk factors[J].Expert Rev Cardiovasc Ther,2021,19(9):787-800.DOI:10.1080/14779072.2021.1964361.
• [7]Abramowitz Y,Jilaihawi H,Chakravarty T,et al.Mitral annulus calcification[J].J Am Coll Cardiol,2015,66(17):1934-1941.DOI:10.1016/j.jacc.2015.08.872.
• [8]Cavalcanti LRP,SáMPBO,PerazzoáM,et al.Mitral annular calcification:association with atherosclero sis and clinical implications[J].Curr Atheroscler Rep,2020,22(2):9.DOI:10.1007/s11883-020-0825-3.
• [9]Garg V.The role of Lipoprotein(a)in calcific aortic valve disease:insights from a large-cohort genetic study[J].JAMA Cardiol,2018,3(1):24-25.DOI:10.1001/jamacardio.2017.4267.
• [10]Kronenberg E,Mora S,Stroes ESG,et al.Lipoprotein(a)in athero sclerotic cardiovascular disease and aortic steno sis:a European Atherosclerosis Society consensus statement[J].Eur Heart J,2022,43(39):3925-3946.DOI:10.1093/eurheartj/ehac361.
• [11]Garg PK,Guan W,Karger AB,et al.Lipoprotein(a)and risk for calcification of the coronary arteries,mitral valve,andthoracic aorta:the Multi-Ethnic Study of Atherosclerosis[J].J Cardiovasc Comput Tomogr,2021,15(2):154-160.DOI:10.1016/j.jcct.2020.06.002.
• [12]Silbiger JJ.Anatomy,mechanics,and pathophysiology of the mitral annulus[J].Am Heart J,2012,164(2):163-176.DOI:10.1016/j.ahj.2012.05.014.
• [13]Pagel PS,Diciaula GH,Schroeder AR.Edible model of mitral valve leaflet surface geometry[J].J Cardiothorac Vasc Anesth,2015,29(1):e4-e5.DOI:10.1053/j.jvca.2014.06.011.
• [14]Mas sera D,Kizer JR,Dweck MR.Mechanisms of mitral annular calcification[J].Trends Cardiovasc Med,2020,30(5):289-295.DOI:10.1016/j.tcm.2019.07.011.
• [15]Movva R,Murthy K,Romero-Corral A,et al.Calcification of the mitral valve and annulus:systematic evaluation of effects on valve anatomy and function[J].J Am Soc Echocardiogr,2013,26(10):1135-1142.DOI:10.1016/j.echo.2013.06.014.
• [16]Lee HJ,Seo J,Gwak SY,et al.Risk factors and outcomes with progressive mitral annular calcification[J].J Am Heart Assoc,2023,12(18):e030620.DOI:10.1161/jaha.123.030620.
• [17]Guerrero ME,Grayburn P,Smith RL 2nd,et al.Diagnosis,classification,and management strategies for mitral annular calcification:a heart valve collaboratory position statement[J].JACC Cardiovasc Interv,2023,16(18):2195-2210.DOI:10.1016/j.j cin.2023.06.044.
• [18]Chehab O,Roberts-Thomson R,Bivona A,et al.Management of patients with severe mitral annular calcification[J].J Am Coll Cardiol,2022,80(7):722-738.DOI:10.1016/j.jacc.2022.06.009.
• [19]Marcovina SM.Lipoprotein(a):a genetically determined risk factor for Cardiovascular disease[J].Crit Rev Clin Lab Sci,2023,60(8):560-572.DOI:10.1080/10408363.2023.2229915.
• [20]Nicholls SJ,Nissen SE,Fleming C,et al.Muvalaplin,an oral small molecule inhibitor of Lipoprotein(a)formation:a randomized clinical trial[J].JAMA,2023,330(11):1042-1053.DOI:10.1001/jama.2023.16503.
• [21]王莹,刘臣,周鹏,等.血浆脂蛋白(a)与ST段抬高型心肌梗死患者冠状动脉病变严重程度的关系研究[J].中国介入心脏病学杂志,2020,28(12):675-679.DOI:10.3969/j.issn.1004-8812.2020.12.003.
• [22]Capoulade R,Chan KL,Yeang C,et al.Oxidized phospholipids,lipoprotein(a),and progression of calcific aortic valve stenosis[J].J Am Coll Cardiol,2015,66(11):1236-1246.DOI:10.1016/j.jacc.2015.07.020.
• [23]Tsimikas S.A test in context:Lipoprotein(a):diagnosis,prognosis,controversies,and emerging therapies[J].J Am Coll Cardiol,2017,69(6):692-711.DOI:10.1016/j.jacc.2016.11.042.
• [24]Jawi MM,Frohlich J,Chan SY.Lipoprotein(a)the insurgent:a new insight into the structure,function,metabolism,pathogenicity,and medications affecting Lipoprotein(a)molecule[J].J Lipids,2020,2020:3491764.DOI:10.115 5/2020/3491764.
• [25]Ruscica M,Sirtori CR,Corsini A,et al.Lipoprotein(a):knowns,unknowns and uncertainties[J].Pharmacol Res,2021,173:105812.DOI:10.1016/j.phrs.2021.105812.
• [26]Kamstrup PR,Tybj?rg-Hansen A,Nordestgaard BG.Elevated Lipoprotein(a)and risk of aortic valve stenosis in the general population[J].J Am Coll Cardiol,2014,63(5):470-477.DOI:10.1016/j.jacc.2013.09.038.
• [27]Bergmark BA,O'Donoghue ML,Murphy SA,et al.An exploratory analysis of proprotein convertase subtilisin/Kexin Type 9 inhibition and aortic stenosis in the FOURIER Trial[J].JAMA Cardiol,2020,5(6):709-713.DOI:10.1001/jamacardio.2020.0728.
• [28]Swerdlow DI,Rider DA,Yavari A,et al.Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease:the emerging potential of RNA interference therapeutics[J].Cardiovasc Res,2022,118(5):1218-1231.DOI:10.1093/cvr/cvab100.
• [29]Bonow RO,Carabello BA,Chatterjee K,et al.ACC/AHA2006 guidelines for the management of patients with valvular heart disease[J].J Am Coll Cardiol,2006,48(3):e1-e148.DOI:10.1016/j.jacc.2006.05.021.
• [30]Capoulade R,Yeang C,Chan KL,et al.Association of mild to moderate aortic valve stenosis progression with higher Lipoprotein(a)and Oxidized Phospholipid levels:secondary analysis of a randomized clinical trial[J].JAMA Cardiol,2018,3(12):1212-1217.DOI:10.1001/jamacardio.2018.3798.
• [31] Masson W,Barbagelata L,Oberti P,et al.High lipoprotein(a)levels and mitral valve disease:a systematic review[J].Nutr Metab Cardiovasc Dis,2023,33(5):925-933.DOI:10.1016/j.numecd.2023.01.025.
• [32]Abrignani MG,Maloberti A,Di Fusco SA,et al.Lipoprotein(a):relationships with atherosclerosis and valvular heart disease,and emerging therapies[J].G Ital Cardiol(Rome),2024,25(2):76-87.DOI:10.1714/4187.41756.
• [33]Bortnick AE,Bartz TM,Ix JH,et al.Association of inflammatory,lipid and mineral markers with cardiac calcification in older adults[J].Heart,2016,102(22):1826-1834.DOI:10.113 6/heartjnl-2016-309404.
• [34]Shah N,Riaz H,Kaul R,et al.The relationship between Lipoprotein(α),mitral annular calcification,and mitral stenosis in a large cohort of dyslipidemia patients[J].J Am Coll Cardiol,2018,71(11):A1778.DOI:10.1016/s0735-1097(18)32319-2.
• [35]Kaltoft M,Sigvardsen PE,Afzal S,et al.Elevated lipoprotein(a)in mitral and aortic valve calcification and disease:the Copenhagen General Population Study[J].Atherosclerosis,2022,349:166-174.DOI:10.1016/j.athero sclerosis.2021.11.029.
• [36]Obisesan OH,Kou M,Wang FM,et al.Lipoprotein(a)and sub clinical vascular and valvular calcification on cardiac computed tomography:the atherosclerosis risk in communities study[J].J Am Heart Assoc,2022,11(11):e024870.DOI:10.1161/jaha.121.024870.
• [37]吴同薇.冠心病患者中脂蛋白(a)与心脏瓣膜病相关性研究[D].广东:南方医科大学,2020.DOI:10.27003/d.cnki.gojyu.2020.000941.
• [38]Thanassoulis G,Campbell CY,Owens DS,et al.Genetic associations with valvular calcification and aortic stenosis[J].N Engl J Med,2013,368(6):503-512.DOI:10.1056/NEJMoa1109034.
• [39]赵振燕.脂蛋白(a)与钙化性主动脉瓣狭窄的关系[J].中国循环杂志,2021,36(9):920-923.DOI:10.3969/j.issn.1000-3614.2021.09.016.
• [40]Hadi HA,Carr CS,AI Suwaidi J,et al.Endothelial dysfunction:cardiovascular risk factors,therapy,and outcome[J].Vasc Health Risk Manag,2005,1(3):183-198.
• [41]Peeters FECM,Meex SJR,Dweck MR,et al.Calcific aortic valve stenosis:hard disease in the heart:a biomolecular approach towards diagnosis and treatment[J].Eur Heart J,2018,39(28):2618-2624.DOI:10.1093/eurheartj/ehx653.
• [42]Zheng KH,Tsimikas S,Pawade T,et al.Lipoprotein(a)and Oxidized Phospholipids promote valve calcification in patients with aortic stenosis[J].J Am Coll Cardiol,2019,73(17):2150-2162.DOI:10.1016/j.jacc.2019.01.070.
• [43]Sun W,Li H,Yu Y,et al.MEKK3 is required for lysophosphatidic acid-induced NF-κB activation[J].Cell Signal,2009,21(10):1488-1494.DOI:10.1016/j.cellsig.2009.05.007.
• [44]Pibarot P,Rosenhek R,Lancellotti P.Lipoprotein(a):a promising target in the treatment of stenotic valvular diseases[J].Eur Heart J Cardiovasc Imaging,2016,17(5):498-499.DOI:10.1093/ehjci/jew022.
• [45]Bouchareb R,Mahmut A,Nsaibia MJ,et al.Autotaxin derived from Lipoprotein(a)and valve interstitial cells promotes inflammation and mineralization of the aortic valve[J].Circulation,2015,132(8):677-690.DOI:10.1161/CIRCULATIONAHA.115.016757.
• [46]Chehab O,Roberts-Thomson R,Bivona A,et al.Management of patients with severe mitral annular calcification:JACC stateof-the-art review[J].J Am Coll Cardiol,2022,80(7):722-738.DOI:10.1016/j.jacc.2022.06.009.
• [47]牛冠男,宋光远,吴永健.经导管二尖瓣置换术在特殊类型二尖瓣疾病患者中的应用[J].中国介入心脏病学杂志,2021,29(8):473-476.DOI:10.3969/j.issn.1004-8812.2021.08.009.
• [48]Thomas PE.Vedel-Krogh S,Nielsen SF,et al.Lipoprotein(a)and risks of peripheral artery disease,abdominal aortic aneurysm,and major adverse limb events[J].J Am Coll Cardiol,2023,82(24):2265-2276.DOI:10.1016/j.jacc.2023.10.009.